a patient with pulmonary hypertension is receiving sildenafil quizlet

Patients with pulmonary arterial hypertension (PAH) are receiving sildenafil therapy, a widely used treatment that targets the reduction of pulmonary vascular resistance, enhancement of cardiac function, and improvement of exercise capacity. Sildenafil exerts its effect by inhibiting phosphodiesterase 5 (PDE5), which leads to increased nitric oxide-mediated vasodilation and a consequent decrease in pulmonary arterial pressure.

However, when administering sildenafil for PAH, it is crucial to be aware of its potential side effects and possible drug interactions. The most frequently reported side effects include headaches, facial flushing, digestive issues, and visual disturbances. Moreover, the concomitant use of sildenafil with nitrate medications can result in dangerously low blood pressure, necessitating the avoidance of such combinations in treatment regimens. Patients with a history of cardiovascular disease should exercise caution with sildenafil due to the potential increased risk of cardiac events. Additionally, although infrequent, sildenafil can lead to severe vision and hearing impairments.

Patients undergoing sildenafil therapy should have their blood pressure and heart rate monitored on a regular basis and consult a healthcare provider promptly if they experience any adverse symptoms. Compliance with the physician's instructions is essential; patients should not alter the dosage or discontinue the medication without professional guidance. Throughout the treatment, it is also important to consider lifestyle modifications, such as smoking cessation, alcohol consumption limitation, adherence to a healthy diet, and engagement in moderate physical activity, to optimize therapeutic outcomes and overall quality of life.